FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis

Why It Matters

Linerixibat fills a long‑standing therapeutic gap, offering PBC patients a disease‑specific option to alleviate debilitating itch and enhance quality of life. Its approval also signals growing regulatory openness to symptom‑focused therapies in rare liver disorders.

Key Takeaways

• FDA approves linerixibat for PBC‑related cholestatic itch
• GLISTEN trial showed −2.86 WI‑NRS vs −2.15 placebo
• Itch relief evident by week 2, mean difference −0.71
• Sleep interference improved, mean difference −0.53
• Diarrhea led to 4% discontinuations

Pulse Analysis

Cholestatic pruritus has long been a hidden burden for individuals with primary biliary cholangitis, a rare autoimmune liver disease that disrupts bile flow and precipitates fatigue, sleep loss, and diminished quality of life. Conventional management relied on off‑label antihistamines, rifampicin, or opioid antagonists, each offering modest relief and a risk of systemic side effects. The absence of a dedicated, FDA‑cleared therapy left clinicians scrambling for palliative measures, underscoring a critical unmet need in hepatology care.

Linerixibat, an ileal bile‑acid transporter inhibitor, addresses the itch at its biochemical source by preventing enterohepatic recirculation of pruritogenic bile acids. In the GLISTEN trial, 238 patients received either linerixibat or placebo for 24 weeks, achieving a least‑squares mean reduction of 2.86 points on the worst‑itch numeric rating scale versus 2.15 points for placebo. Notably, the therapeutic effect manifested by week two, with a mean difference of 0.71 points, and translated into meaningful sleep‑interference improvements (−0.53 mean difference). These data suggest that rapid symptom control can mitigate the downstream psychosocial impacts that chronic itch imposes on PBC patients.

Safety profiling revealed diarrhea as the predominant adverse event, yet it remained mild for most and prompted discontinuation in only four percent of the treated cohort. The drug’s orphan‑drug designation and priority review status in multiple regions position it for swift global rollout, potentially reshaping the market for cholestatic itch therapies. For payers and providers, linerixibat offers a cost‑effective, disease‑targeted option that could reduce ancillary medication use and improve patient adherence, ultimately translating into lower overall healthcare expenditures for a condition that has historically been under‑treated.